Antimicrobial activities of synthetic bismuth compounds against Clostridium difficile.
Clostridium difficile is a major nosocomial pathogen responsible for pseudomembranous colitis and many cases of antibiotic-associated diarrhea. Because of potential relapse of disease with current antimicrobial therapy protocols, there is a need for additional and/or alternative antimicrobial agents for the treatment of disease caused by C. difficile. We have synthesized a systematic series of 14 structurally simple bismuth compounds and assessed their biological activities against C. difficile and four other gastrointestinal species, including Helicobacter pylori. Here, we report on the activities of six compounds that exhibit antibacterial activities against C. difficile, and some of the compounds have MICs of less than 1 microgram/ml. Also tested, for comparison, were the activities of bismuth subcitrate and ranitidine bismuth citrate obtained from commercial sources. C. difficile and H. pylori were more sensitive both to the synthetic bismuth compounds and to the commercial products than were Escherichia coli, Pseudomonas aeruginosa, and Proteus mirabilis, and the last three species were markedly resistant to the commercial bismuth salts. Testing with human foreskin fibroblast cells revealed that some of the synthetic compounds were more cytotoxic than others. Killing curves for C. difficile treated with the more active compounds revealed rapid death, and electron microscopy showed that the bismuth of these compounds was rapidly incorporated by C. difficile. Energy dispersive spectroscopy X-ray microanalysis of C. difficile cells containing electron-dense material confirmed the presence of internalized bismuth. Internalized bismuth was not observed in C. difficile treated with synthetic bismuth compounds that lacked antimicrobial activity, which suggests that the uptake of the metal is required for killing activity. The nature of the carrier would seem to determine whether bismuth is transported into susceptible bacteria like C. difficile.
Mahony
D E
DE
Department of Microbiology, Dalhousie University, Halifax, Nova Scotia, Canada. David.E.Mahony@Dal.Ca
Lim-Morrison
S
S
Bryden
L
L
Faulkner
G
G
Hoffman
P S
PS
Agocs
L
L
Briand
G G
GG
Burford
N
N
Maguire
H
H
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects; D001729:Bismuth / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D016360:Clostridioides difficile / Q000187:drug effects* / Q000648:ultrastructure; D015169:Colony Count, Microbial; D004577:Electron Probe Microanalysis; D006801:Humans; D008854:Microscopy, Electron; D009942:Organometallic Compounds / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D001729:Bismuth